Navigation Links
A new indicator for breast cancer relapse identified
Date:6/19/2012

This press release is available in Spanish.

Researchers at the IMIM (Institut de Recerca Hospital del Mar) have proven that the absence of the 14-3-3 protein sigma in breast cancer cells is directly associated with these cells' capacity to activate the signalling of a protein complex called NF-kB, which is related to tumour progression. The activation of NF-kB in tumours was also identified as the best indicator for relapse in breast cancer patients, compared to other parameters currently used, such as the presence of affected ganglions or the tumour's size and degree. The investigators have also described a group of genes that are activated in breast cancer cells and that are also associated with a poor prognosis in other types of tumours.

Previous studies had detected that the 14-3-3 protein sigma was not present in the tumours of many breast cancer patients. They have now discovered that 'the lack of this protein does not in itself establish a prognosis factor for these types of cancer, although the NF-kB complex is an essential requirement for it to remain active chronically, as it is associated with tumour invasion and metastasis or, stated differently, the progression of the tumour', comments Llus Espinosa, study coordinator and researcher in the IMIM stem cells and cancer research group.

Breast cancer is most common among women in Western countries and relapse and metastasis are the fatal consequences of this disease. Identifying the mechanisms involved in the survival of breast cancer cells and their ability to colonise other tissues are crucial issues for improving treatment. With the participation of some 100 patients, this study analysed the possible usefulness of determining the lack of the 14-3-3 sigma and/or the activation of NF-kB in tumour cells as a factor in prognosis and diagnosis, as well as for future clinical and therapeutic applications.

The results obtained from this project have opened up new roads of investigation that will have to centre on identifying the pharmaceuticals that induce the expression of the 14-3-3 protein sigma in breast tumours and characterise their effect on tumour cells. They also hope to define which genes activated by the NF-kB complex are important for tumour progression in this group of patients and to study their potential as possible therapeutic targets.

According to Espinosa 'This opens up the possibility of researching and employing specific therapeutic strategies for this concrete group of patients who, in principle, have bad prognoses and an especially high risk of relapse'.

The study was initially led and developed at the IMIM by Dr Llus Espinosa's and Anna Bigas' group and collaboration from researchers and doctors from the Hospital del Mar, the Jimenez Daz Foundation, the Barcelona Institute of Biomedical Research (IRB) and Pompeu Fabra University.


'/>"/>
Contact: Marta Calsina
mcalsina@imim.es
34-933-160-680
IMIM (Hospital del Mar Research Institute)
Source:Eurekalert

Related biology news :

1. AAO-HNS releases updated Clinical Indicators
2. Researchers identify need to sample multiple tumor zones in breast cancer
3. UCSB anthropologists finds high levels of omega-3 fatty acids in breast milk of Amerindian women
4. Cardio fitness levels of breast cancer patients may affect survival
5. Newly discovered breast milk antibodies help neutralize HIV
6. Breast-fed babies gut microbes contribute to healthy immune systems
7. Heparin-like compounds inhibit breast cancer metastasis to bone
8. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
9. Study sheds new light on importance of human breast milk ingredient
10. Molecule found that inhibits estrogen, key risk factor for endometrial and breast cancers
11. MicroRNA controls malignancy and resistance of breast cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology: